Exploring Advanced Monoclonality Assurance Techniques
In today’s cutting-edge biomedical landscape, ensuring monoclonality in cell line development is crucial for the stability of protein, cellular, and gene therapies. Join us in a fascinating opportunity to gain insights into improving monoclonality assurance at our upcoming webinar.
Webinar Overview and Key Benefits
This free webinar promises to impart valuable knowledge on practical strategies designed to minimize the risk of false positives, commonly referred to as ghost wells. Attendees will learn about innovative imaging techniques such as nanodroplet and whole well brightfield imaging, which are pivotal in validating workflows that boast a 99.99% Probability of Clonality. A featured speaker will delve into the impact of artificial intelligence and data centralization, emphasizing how these advancements can decrease the demands for manual image analysis by over 50%.
Enhancing Workflow for Clonality Assurance
In the session led by Adam Causer, Global Product Manager at Solentim Portfolio, participants will gain a comprehensive understanding of an end-to-end workflow geared towards achieving a high probability of clonality. This workflow not only promises enhanced reliability but also digitalizes and automates the evidence generation process required for Investigational New Drug (IND) submissions.
Minimizing Risks with Innovative Techniques
Most importantly, attendees can look forward to actionable insights on reducing ghost well risks through gentle, automated single-cell deposition. The session will showcase how to implement workflows that deliver probabilities exceeding 99.99% when coupled with high-throughput whole-well imaging. Efficiency and throughput will remain uncompromised, facilitated by AI-powered data management and analytics.
Webinar Details and Participation
Mark your calendars for this engaging webinar, which is set to take place on a Tuesday with two live broadcasts. The first session will be at 9am CET/EU-Central (4pm CST/China), followed by the second at 8am EST/North America (2pm CET/EU-Central). Don't miss out on this opportunity to elevate your understanding of monoclonality assurance!
Join the Life Science Community with Xtalks
Learn more and register now to be part of this enriching experience. Subscribing to our community is a fantastic way to stay ahead in the life sciences field. Xtalks empowers professionals by providing essential knowledge, timely news, and collaborative insights designed to move the industry forward.
About Xtalks
Xtalks - The Life Science Community™ is dedicated to fostering professional growth across pharma, biotech, medtech, and healthcare sectors. It serves as a platform for sharing knowledge through webinars, articles, and podcasts that guide informed decision-making amidst a fast-evolving landscape.
Contact Information
For further inquiries, please reach out to Vera Kovacevic at +1 (416) 977-6555 x371. We encourage you to explore opportunities to collaborate with Xtalks in hosting webinars that highlight important topics in the life science community.
Frequently Asked Questions
What is monoclonality assurance?
Monoclonality assurance is the process of ensuring that a cell line originates from a single progenitor cell, which is essential for the reliability of biotechnological applications.
Why is this webinar important?
This webinar equips participants with advanced techniques to enhance monoclonality assurance, which can significantly impact the success of therapeutic developments.
Who is presenting during the webinar?
Adam Causer, Global Product Manager at Solentim Portfolio of Nova Biomedical, will lead the session and share invaluable insights.
How can I register for the webinar?
Interested individuals can register for the webinar by visiting the Xtalks website and following the registration prompts for the event.
What topics will be covered in the webinar?
The topics include minimizing ghost well risks, achieving high probabilities of clonality, and leveraging AI-powered data management in cell line development.
